1 |
Xia BJ, Chen D, Zhang JS, et al. Osteoarthritis pathogenesis: a review of molecular mechanisms[J]. Calcif Tissue Int, 2014, 95(6): 495-505.
|
2 |
Felson DT. Osteoarthritis: new insights. part 1: the disease and its risk factors[J]. Ann Intern Med, 2000, 133(8): 635.
|
3 |
Pereira D, Ramos E, Branco J. Osteoarthritis[J]. Acta Med Port, 2014, 28(1): 99.
|
4 |
Charlier E, Deroyer C, Ciregia F, et al. Chondrocyte dedifferentiation and osteoarthritis (OA)[J]. Biochem Pharmacol, 2019, 165: 49-65.
|
5 |
Pap T, Korb-Pap A. Cartilage damage in osteoarthritis and rheumatoid arthritis: two unequal siblings[J]. Nat Rev Rheumatol, 2015, 11(10): 606-615.
|
6 |
Theocharis AD, Manou D, Karamanos NK. The extracellular matrix as a multitasking player in disease[J]. FEBS J, 2019, 286(15): 2830-2869.
|
7 |
Liu HC, Liu YL, Chen B. Antagonism of GPR4 with NE 52-QQ57 and the suppression of AGE-induced degradation of type Ⅱ collagen in human chondrocytes[J]. Chem Res Toxicol, 2020, 33(7): 1915-1921.
|
8 |
Simpson RJ, Lim JW, Moritz RL, et al. Exosomes: proteomic insights and diagnostic potential[J]. Expert Rev Proteom, 2009, 6(3): 267-283.
|
9 |
Tran TH, Mattheolabakis G, Aldawsari H, et al. Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases[J]. Clin Immunol, 2015, 160(1): 46-58.
|
10 |
Barile L, Vassalli G. Exosomes: therapy delivery tools and biomarkers of diseases[J]. Pharmacol Ther, 2017, 174: 63-78.
|
11 |
Song H, Li X, Zhao Z, et al. Reversal of osteoporotic activity by endothelial cell-secreted bone targeting and biocompatible exosomes[J]. Nano Lett, 2019, 19(5): 3040-3048.
|
12 |
Sáez T, de Vos P, Kuipers J, et al. Exosomes derived from monocytes and from endothelial cells mediate monocyte and endothelial cell activation under high d-glucose conditions[J]. Immunobiology, 2019, 224(2): 325-333.
|
13 |
Davies LC, Heldring N, Kadri N, et al. Mesenchymal stromal cell secretion of programmed death-1 ligands regulates T cell mediated immunosuppression[J]. Stem Cells, 2017, 35(3): 766-776.
|
14 |
Jun Z, Xinmeng J, Yue L, et al. Jumonji domain containing-3 (JMJD3) inhibition attenuates IL-1β-induced chondrocytes damage in vitro and protects osteoarthritis cartilage in vivo[J]. Inflamm Res, 2020, 69(7): 657-666.
|
15 |
Théry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses[J]. Nat Rev Immunol, 2009, 9(8): 581-593.
|
16 |
Ying C, Wang R, Wang Z, et al. BMSC-exosomes carry mutant HIF-1α for improving angiogenesis and osteogenesis in critical-sized calvarial defects[J]. Front Bioeng Biotechnol, 2020, 8: 565561.
|
17 |
Liang RM, Zhao JM, Li B, et al. Implantable and degradable antioxidant poly(ε-caprolactone)-lignin nanofiber membrane for effective osteoarthritis treatment[J]. Biomaterials, 2020, 230: 119601.
|
18 |
Kong N, Ji XY, Wang JQ, et al. ROS-mediated selective killing effect of black phosphorus: mechanistic understanding and its guidance for safe biomedical applications[J]. Nano Lett, 2020, 20(5): 3943-3955.
|
19 |
Osama A, Zhang J, Yao J, et al. Nrf2: a dark horse in Alzheimer's disease treatment[J]. Ageing Res Rev, 2020, 64: 101206.
|
20 |
Bollong MJ, Lee G, Coukos JS, et al. A metabolite-derived protein modification integrates glycolysis with KEAP1-NRF2 signalling[J]. Nature, 2018, 562(7728): 600-604.
|
21 |
Hou RL, Liu X, Yan JJ, et al. Characterization of natural melanin from Auricularia auricula and its hepatoprotective effect on acute alcohol liver injury in mice[J]. Food Funct, 2019, 10(2): 1017-1027.
|
22 |
Wang P, Gao YM, Sun X, et al. Hepatoprotective effect of 2'-O-galloylhyperin against oxidative stress-induced liver damage through induction of Nrf2/ARE-mediated antioxidant pathway[J]. Food Chem Toxicol, 2017, 102: 129-142.
|